ABSTRACT
Objective To explore ways of enhancing the therapeutic level of the neurology department and reducing the economic burdens of patients. Methods Relevant materials were collected by means of evidence based medicine to optimize therapeutic schedules, with cerebral infarction being the pitching in point. Results Prior to the adoption of evidence based medicine, the average length of stay, the effective rate of treatment and the expenses for single entity diseases were respectively 17.83?13.44, 89.91% and 4 550.70 yuan, whereas after the adoption of evidence based medicine, they were respectively 15.38?11.37, 94.16% and 3 942.88 yuan. Conclusion Evidence based management is a means of scientific management. Its application in the department of neurology has produced a marked effect and it is worthy to be spread.
ABSTRACT
Objective:To induce the specific cytotoxicity of T lymphocytes to the breast cancer cells overexpressing HER 2 by bispecific monoclonal antibodies anti HER 2?anti CD3 and to stimulate natural immunoreactions. Methods:Using SK BR 3 cell line overexpressing HER 2 as target cells, MCF 7 cell line as control cells, and T lymphocytes as effector cells, the biological function of BsAb anti HER 2?anti CD3 was studied, including growth inhibition of target cells, proliferation of effect cells, and cytotoxicity of lymphocytes mediated to SK BR 3. The measuring methods included MTT(measurement of tetrazplium), 3H thymidine incorporation assay system.Results:BsAb anti HER 2?anti CD3 had the function of MAbHER 2 and MAbCD3, which inhibited growth of SK BR 3 and accelerated proliferation of T lymphocytes from normal donors. BsAb anti HER 2?anti CD3 mediated more significant cytotoxicity of T lymphocytes to SK BR 3 than MAb HER 2.The best ratio of effector cells to target cells was 20∶1. Conclusion:BsAb anti HER 2?anti CD3 bound to the breast cancer cells overexpressing HER 2 and T lymphocytes and mediated significant cytotoxicity of T lymphocytes to the breast cancer cells overexpressing HER 2, indicating BsAb anti HER 2?anti CD3 had significant antitumor function.